|
m2-toxin: a selective ligand for M2
muscarinic receptors obtained from the venom of the east African green
mamba (Dendroaspis angusticeps).
Jigany MC et al. m2-Toxin: A Selective Ligand for M2
Muscarinic Receptors. Molecular Pharmacology (1999) 56 (5): 933-937
M-6434:
a non-subtype selective agonist of α1-adrenoceptors
with vasoconstricting actions. It has been used as a pharmacological tool to
investigate adrenoceptors.
Ohnishi H et
al. Pharmacological properties of
2-[(5-chloro-2-methoxyphenyl)azo]-1H-imidazole (M6434). Arzneimittelforschung
(1981) 31(9):1425-9
MAb: monoclonal antibody
MAC:
minimum alveolar concentration
Macleod,
John JR (1876 - 1935): Scottish-born Canadian
physiologist who shared the 1923 Nobel Prize for Physiology and Medicine with
Banting 'for the discovery of insulin'.
http://nobelprize.org/medicine/laureates/1923/macleod-
bio.html
Macrolides:
a class of antibiotics effective in the treatment of
gram-positive bacteria. They inhibit bacterial protein synthesis by binding to
the 50S subunit of bacterial ribosomes (the same binding site as that for
chloramphenicol and clindamycin) and inhibit the translocation of aminoacyl
t-RNA. They are usually bacteriostatic but at high concentrations are
bactericidal. Examples include erythromycin, azithromycin,
clarithromycin, oleandromycin and troleandromycin. The name macrolide derives
from their large size (typically 14 or 16 carbon atoms) and that they are
lactones (which are cyclic esters).
Macrophage
inflammatory protein: a murine CXC chemokine
induced by LPS, TNF-α and IL-1 . It upregulates the production of
neutrophil integrin (CD11b/CD18), stimulated neutrophil respiratory burst and
acts as a neutrophil chemmoattractant.
Macular
mutant mice: an animal model of Menkes' kinky-hair
disease.
Shiraishi N
et al. Copper metabolism in the macular mutant mouse: an animal model of
Menkes's kinky-hair disease. Biol Neonate (1988) 54(3):173-80
Maculotoxin: a neurotoxin obtained from the venom glands of the blue-ringed
octopus Hapalochlaena maculosa and now known to be the same as tetrodotoxin.
It acts by blocking sodium channels in neurones.
Magnus
bath: a small glass container in which tissue can be suspended in
solution to observe the effects of drugs on it. Named after the German
physiologist Rudolf Magnus (1873-1927).
MAIDS:
murine acquired immunodeficiency
syndrome, the mouse and rat equivalent of AIDS.
Maitotoxin
(MTX): a potent marine dinoflagellate toxin and a potent activator of
voltage-sensitive calcium channels and increases the flow of Ca2+ ions across a variety of cell membranes. It has
been used as a pharmacological tool.
Major
tranquilizers: also known as antipsychotics.
Mamba
toxins: protein toxins from black (Dendroaspis polylepis) and green
(Dendroaspis angusticeps) mamba snakes. They are neurotoxins and include
dendrotoxins which have little or no antiprotease activity but block certain
neuronal voltage-dependent potassium channel subtypes of the Kv1 subfamily.
They are often used as pharmacological tools in the study of K+
channels.
Harvey
AL. Twenty years of dendrotoxins. Toxicon (2001) 39(1):15-26
Mammalian
cell transformation test: tests using cultured mammalian
cell systems to detect phenotypic changes in vitro which are induced by
chemical substances associated with malignant transformation in vivo.
Mammillary
model: a pharmacokinetic model which represents the human body by a
limited set of compartments which usually have no physiological or anatomical
equivalent. This model has a central compartment surrounded by others connected
only to the central compartment, ie the compartments are in parallel. The name
is derived from the Latin word for breast. See also catenary
model.
Mancude
ring: a ring in an organic molecule having the maximum number of
noncumulative
double bonds. Common examples in medicinal chemistry include
benzene, indene and indole.
Mann-Whitney
U-test: also referred to as the Wilcoxon Rank-sum test, a statistical
method for the comparison of two completely independent random samples (x and
y). It was proposed by Mann and Whitney (in 1947) and by Wilcoxon (in 1947) as
a test to determine whether the degree of overlap between the the observed
distributions of the groups is less than that expected by chance. The null
hypothesis that the two samples are drawn from a single population (and there
are no differences between the populations).
Mannoproteins: branched a-linked mannose polymers linked
to proteins via an N-acetylglucosamine-N-acetylglucosamine moiety. They are
essential components of fungal cell membranes.
Mannoprotein
binders: also known as mannoprotein inhibitors, a class of antifungal
compounds which bind to fungal wall mannoproteins causing the cell to
leak its intracellular components leading to cell death. Examples include the
pradimicins and benanomicins.
Manumycins:
a class of antibiotic isolated from Streptomyces spp such
as Streptomyces nodosus. Manumycin A is a farnesyltransferase inhibitor
which can induce apoptosis in tumor cells.
MAO:
monoamine oxidase
MAOI: monoamine oxidase inhibitor
MAP
kinases (mitogen-activated protein kinase): a
family of about 13 cellular enzymes which are stimulated by extracellular
stimuli such as mitogens and which have a broad range of cellular functions
such as gene expression, cell differentiation, apoptosis and mitosis. Several
groups of MAP kinases exist including the ERK1/ERK2 MAP kinase cascade which is
activated by a variety of hormones and growth factors.
Another
group of MAP kinases are potently activated by cellular stress and this group
includes the c-Jun amino terminal kinases (JNKs) and p38 MAP kinase isoforms. These
enzymes are important targets for anticancer therapy.
Marble burying: an animal model for both anxiety and obsessive compulsive disorders. Typically, mice are individually housed in cages containing 5cm of hard wood bedding and marbles are placed in each cage. Mice pretreated with anxiolytic agents show less marble burying behaviour compared to untreated mice.
Margatoxin
(MgTX): a 39 amino acid peptide and voltage-dependent potassium channel
blocker isolated from the venom of the scorpion (Centruroides
margaritatus). It has been used as a pharmacological tool to
investigate potassium channels.
Garcia-Calvo
M et al. Purification, characterization, and biosynthesis of margatoxin,
a component of Centruroides margaritatus venom that selectively inhibits voltage-dependent
potassium channels. J Biol Chem(1993) 268; 18866-74
See
also http://www.jbc.org/cgi/reprint/268/25/18866.pdf
Mast
cells: cells found in connective tissue and which produce an exclusive
family of proteases (tryptases and chymases) along with mediators of
inflammation such as histamine and eicosanoids. They play an important role in
allergy and anaphylaxis. See http://en.wikipedia.org/wiki/Mast_cell
Mast
cell stabilizers: also known as mast cell degranulation
inhibitors, compounds which prevent mast cells from releasing pro-inflammatory
compounds such s histamine and eicosanoids which are present in their storage
vesicles. Mast cell stabilizers include cromoglicate sodium and are used in the
treatment of allergies, food allergies, asthma, allergic conjunctivitis and
allergic rhinitis.
Mastoparan: a mast cell degranulating peptide and toxin obtained from
the venom of Vespula lewisii, the yellow jacket wasp. It is a
tetradecapeptide which acts as a calmodulin antagonist and activates
phospholipase A2.
Higashijima
T et al . Mastoparan, a peptide toxin from wasp venom, mimics receptors
by activating GTP-binding regulatory proteins (G proteins) J Biol Chem (1988)
263; 6491 See http://www.jbc.org/cgi/reprint/263/14/6491.pdf
Matlystatins: a group of type IV collagenase inhibitors isolated from the
bacterium Actinomadura atramentaria. Matlystatins A, B, D, E and F are
known.
Matrixins:
also known as matrix metalloproteases.
Maurotoxin
(MTX): a basic, single chain 34 amino acid polypeptide and potassium
channel blocker obtained from the Tunisian chactoid scorpion Scorpio
maurus. It shows 29-68% sequence identity with other potassium channel
toxins and has been used as a pharmacological tool to study potassium
channels.
Maximal
agonist effect (MAE): also known as intrinsic effect
(although maximal agonist effect is the preferred term), a measure of the
ability of a compound to elicit receptor activation and a physiological or
pharmacological response such as changes in enzyme activity or contraction of
an isolated muscular tissue. The maximal response attainable by an agonist is
100% and this is equivalent to an intrinsic activity value of 1.0. Partial
agonists have values of less than one and antagonists, which bind to the
receptor but which do not elicit any response have a value of zero. Inverse
agonists, however, have intrinsic activity values from zero to minus 1.0. Super
agonists, on the other hand, have values above 1.0.
Maximal
electroshock seizure (MES) test: a method to test the
effects of anticonvulsant drugs. Typically, the test drug is given about
45 minutes prior to the application of an alternating current of 50 Hz and 150
mA applied via bicorneal electrodes for 0.2 sec. MES causes tonic convulsions
of the hindlimb (tonic extension) and the duration of the convulsion, effects
on seizure protection and mortality are taken as indicators of the efficacy of
the test drug.
MCA:
middle cerebral artery, a
common site for occlusion to induce focal ischaemia in the brain.
MCAO: middle cerebral artery occlusion.
MCH: melanin-concentrating hormone
MCI-
186: a radical scavenger (3-methyl-1-phenyl-2-pyrazolin-5-one ) and
anti-oxidant compound. It has been shown to protect animals against the effects
of ischaemia probably by inhibiting lipoxygenases.
McN-A-
343: an M1 muscarinic receptor agonist and
postganglionic nicotinic receptor agonist
(4-(m-chlorophenyl-carbamoyloxy)-2- butynyltrimethylammonium chloride) used as
a pharmacological tool to investigate these receptors and postganglionic
nicotinic receptors.
MDA:
methylenedioxyamphetamine (also
known as tenamfetamine), a hallucinogen, designer drug and drug
of abuse. It is also known as the 'love drug' and 'mellow drug of America'.
MDMA: 3,4-methylenedioxymethamphetamine, a
recreational
drug more commonly known as ecstasy.
MDR:
multidrug resistance
MDR:
mitochondrial diazepam binding inhibitor receptor
MDX
mouse: an animal model for Duchenne and Becker muscular dystrophy
(DMD/BMD) which lacks the muscle protein dystrophin. This mutation is X
chromosome-linked and this defect produces viable animals which have high serum
levels of muscle enzymes and have histological lesions similar to those found
in human muscular dystrophy.
Me-again
drug: like a me-too drug, this is similar to one already
developed but in this case it has been developed by the same company.
Me-too
drug: a compound which is structurally related to a known compound and
which contains only minor pharmacological and chemical differences. There are
many examples of me-too drugs for example the family of anti-ulcer H2
blockers which includes cimetidine, ranitidine and famotidine.
The diagram below shows their structures and structural similarities in blue.
Cimetidine was first to enter the market in about 1976 followed by ranitidine
in about 1981 then famotidine in 1985. They are all used to treat peptic
ulcers.

Mean
residence time (MRT): the average time a drug remains
in the body after a single dose has been given. MRT is expressed as area under
the first moment vs time curve divided by the area under the concentration vs
time curve.
Mebendazole: a broad-spectrum benzimidazole antihelminthic compound
used to treat threadworm, roundworm, whip worm and hookworm infections in
humans and against lungworms in horses, cats and dogs in addition. Mebendazole
is also used to treat trichinosis (a gastrointestinal worm infection)
particularly at the muscular stage of Trichinella spiralis in animals.
Mecamylamine: a nicotinic receptor antagonist used to treat
hypertension. It is being investigated as therapy to help quit smoking.
Mechanogated
membrane ion channels: also known as mechanosensitive
(MS) ion channels, ion channels which are activated by mechanical forces rather
than chemical agonists.
Hamill OP and McBride DW. The pharmacology of mechanogated membrane ion
channels. Pharmacological Reviews (1996) Vol 48; 231-252
Mechanogated
ion channel blockers: compounds blocking
mechanogated membrane ion channels. Examples include gadolinium, amiloride
and gentamicin.
MED:
minimum effective dose
Median
effective dose (ED50): the dose of a drug
required to illicit 50% of the maximum possible effect.
Median
lethal dose (LD50): the dose of a drug found to
cause deaths in 50% of a population of test animals.
Mediator:
any compounds which can illicit or help illicit an inflammatory or
allergic response. Examples include prostaglandins, histamine and
serotonin.
Meglitinides: a group of drugs used to treat type 2 (non-insulin-dependent
diabetes). Examples include nateglinide and repaglinide. They are non-sulphonylureal
insulin secretagogues which lower blood sugar levels by increasing the release
of insulin from the pancreas.
Melanin-
concentrating
hormone (MCH): a 19 amino acid cyclic peptide mainly
expressed in the hypothalamus and implicated in the control of general arousal
and goal-orientated behaviour in mammals. It also appears to play an essential
role in the regulation of food intake. It is an orexigenic (ie increases
appetite and food intake) hypothalamic neuropeptide. MCH is synthesized
primarily in the lateral hypothalamus and zona incerta.
Melanin-
concentrating
hormone receptors (MCHR): receptors for melanin-concentrating
hormone of which two are currently known, ie hMCH-1R and hMCH-2R, for which
MCH is a natural ligand. They are implicated in the control of feeding
behaviour.
Melanin-
concentrating
hormone (MCH) antagonists: compounds which block the
effects of melanin-concentrating hormone and so suppress appetite. They
are being developed for the treatment of obesity and include SNAP-7941, NBI-1A
and NBI-1B.
Melanocortins
(MC): a group of endogenous peptides which include α-melanocyte-stimulating
hormone (α-MSH and also known as α-melanotropin), β-MSH and
γ-MSH and adrenocorticotrophic hormone (ACTH). They are derived from the
pro-opiomelanocortin gene and the melanocortins have important physiological
functions in energy balance, sexual function, pigmentation and inflammation. The
melanocortin system is responsible for the maintenance of energy balance via
the regulation of both food intake and energy expenditure.
Melanocortin
receptors: a family of G protein-coupled receptors (GPCRs)
of which five are currently known, MC1, MC2, MC3,
MC4 and MC5, and for which melanocortins are the
natural ligands.
Melanocyte
stimulating hormones (MSH): also known as intermedins,
peptide hormones produced in cells in the intermediate lobe of the
hypothalamus. Three are known , α-MSH (melanotropin), β-MSH and
γ-MSH. They stimulate the synthesis and release of melanin by melanocytes
(they are melanogenic) and play a role in appetite and sexual function.
Melanocyte-
stimulating
hormone antagonists: compounds which antagonize the
effects of melanocyte-stimulating hormone. Examples include the agouti
protein and Met-Pro-D-Phe-Arg-D-Trp-Phe-Lys-Pro-Val-NH2. They are of
potential use in increasing food intake.
Melanotropin:
also known as α-melanocyte stimulating hormone (α-MSH) .
Melatonin:
a pineal gland hormone
(N-[2-(5-methoxy-1H-indol-3-yl)ethyl]acetamide) first isolated around 1958
which was found to be primarily synthesized in a circadian manner with
peak secretion occurring during nighttime. It has endocrinological,
neurophysiological and behavioural functions and is the subject of research
into disordered circadian rhythms seen in sleep disorders in the elderly and in
shift workers and in jet-lag. Melatonin shows a wide species difference in its
binding sites and binds to specific receptors in the suprachiasmatic nucleus
in the hypothalamus. Melatonin is synthesized from the dietary amino
acid L-tryptophan which is converted to 5-hydroxytryptophan from which
5-hydroxytryptamine (5-HT) is made. 5-HT is converted to melatonin in a
two-step process mainly in the pineal gland. Melatonin has been used in
veterinary medicine to control oestrus.
Melatonin
receptors: G protein-coupled receptors for the peptide hormone melatonin.
Three are currently known, ie MT1, MT2 and MT3. They
mediate the effects of melatonin, ie they control sleep.
Melphalan:
an alkylating agent and anticancer agent used
clinically to treat multiple myleoma, advanced ovarian adenocarcinoma, advanced
breast cancer, childhood neuroblastoma and polycythaemia vera (excess
production of erythrocytes as a result of a proliferative abnormality).
Melphalan is also used to treat multiple myelomas in cats and dogs.
Memantine: a drug used to treat moderate to severe dementia in Alzheimer's
disease. It is a potent NMDA receptor antagonist which inhibits
glutamate transmission in the brain. It binds to the NMDA-operated cation
channels and blocks this ion channel. It does not induce psychotropic effects
or memory impairment and has 5-HT3 antagonist actions. Memantine is
also a dopamine-releasing drug.
Membrane
labilizers: compounds which make membranes less
stable. Examples include veratridine and retinol.
Membrane
stabilizer: compounds which make membranes more
stable. Examples include citicoline (cytidine-5-diphosphocholine; CDP-choline)
which is a naturally occurring nucleotide derivative. It may reduce central
nervous system ischaemic injury by stabilizing cell membranes and may also
reduce free radical generation. Polaxymer 188 may be of use in treating
muscular dystrophy.
Membrane
stabilizing action (MSA): a property observed with a
variety of drugs such as β-blockers such as propranolol and acebutolol.
This action may be beneficial in protection against posthypoxic cardiac
contractile abnormalities and metabolic disturbances.
Membrane
transporter: a carrier-mediated, energy-consuming
system to transport molecules such as water-soluble vitamins, organic cations,
amino acids, dipeptides, monosaccharides, monocarboxylic acids, phosphates and
nucleosides into cells.
Lee VH. Membrane transporters. Eur J Pharm Sci (2000) 11 (2);
S41-50
Meperidine: a synthetic opioid agonist similar in structure to
atropine with morphine-like actions. It is used to treat moderate to severe
pain in humans and animals and as a pre-anaesthetic in animals. It acts
primarily on μ-opioid receptors and has a weak atropine-like action on
muscarinic receptors.
Mephenesin: an aromatic ether and centrally acting muscle relaxant. It
acts by selectively inhibiting polysynaptic excitation of motor neurones
although its mechanism of cellular action is unclear.
Meprobamate: a drug introduced in the mid 1950s for the short-term treatment
of anxiety but which is less effective than benzodiazepines, more hazardous if
overdosed and more prone to induce dependence. It acts at multiple sites in the
central nervous system including sites in the thalamus and limbic system
although its mechanism of action is not fully understood. Carisoprodol (a muscle
relaxant) is a prodrug of meprobamate.
Ramchandani
D et al. Meprobamate-tranquilizer or anxiolytic? A historical perspective. Psychiatr
Q (2006) Spring 77(1);43-53
Mepyramine: a selective H1 histamine receptor inverse agonist (it
also has antagonist effects) which has been used to treat skin inflammation
such as nettle rash in the form of a topical cream.
Mercaptoethylguanidine
sodium succinate: also known as MEG sodium
succinate, a selective inhibitor of inducible nitric oxide synthase (iNOS)
and a peroxynitrite scavenger. This compound may also inhibit cyclooxygenase.
6-
Mercaptopurine: a metabolite of azathioprine and a cytotoxic immunosuppressant
used clinically to treat acute leukaemias and inflammatory bowel disease. It is
a purine antimetabolite first synthesized in 1952. Although its exact mechanism
of action is unclear, it is first converted by hypoxanthine guanine
phosphoribosylpyrophosphate to a thiol nucleotide form which is known to be
cytotoxic. The cytotoxicity of 6-mercaptopurine appears to be due to
interference with de novo purine biosynthesis, inhibition of RNA
synthesis and incorporation into DNA during S phase of the cell cycle leading
to deformation of DNA.
MES:
maximal electroshock seizure
Mescaline:
a hallucinogen and recreational and psychadelic
drug. It is the main active component of peyote and is present in
the peyote cactus.
Mesenteric
window angiogenesis assay: a model of angiogenesis used
to investigate the effect of drugs on neovascularization.
Norrby
K. On the quantitative rat mesenteric-window angiogenesis assay. EXS (1992)
61;282-6
Meso
compounds: stereoisomers which occur when a molecule has two chiral centers
and each chiral center has identical substituents on it. Examples include tartaric
acid.
Mesolimbic-
mesocortical
pathway: a neuronal pathway involved in schizophrenia as there is
excessive dopamine neuronal activity in this pathway in schizophrenia patients.
There are four major dopaminergic systems in the brain, ie the mesolimbic,
mesocortical, nigrostriatal, tuberoinfundibular pathways. It is known that
drugs of abuse induce the release of dopamine in the mesolimbic-mesocortical
pathway. It is sometimes referred to as the pleasure pathway.
Mesylate: a salt or ester of methanesulphonic acid. Examples of mesylates
used in clinical medicine include doxazosin mesylate (used to treat
hypertension and benign prostatic hyperplasia), imatinib mesylate (used in
myeloid leukaemia) and saquinavir mesylate (used in retroviral infections).
Meta-analysis:
also referred to as overview analysis, a statistical method of
combining data obtained from different experiments or trials, providing certain
criteria applicable to each trial are met, which provides greater power and
significance of the overall results.
Metabolic
cage: cages used to house experimental animals and which allow the
separation and collection of urine and faeces so that they may be analysed for
the presence of drugs and/or their metabolites.
Metabolism
(of drugs): also referred to as biotransformation, the
process of detoxifying a drug usually in the liver and preparing it for
excretion from the body. The main reactions involved are divided into two
phases:
Phase
I: oxidation, reduction or hydrolysis. The products of these reactions are
often more potent or more toxic than the parent compounds. In Phase I reactions
the product usually becomes less lipid soluble, more water soluble and more
readily excretable through the kidneys and, as they are often more polar, helps
prevent reabsorption by the kidney tubules. Examples of drugs undergoing Phase
I reactions include pentobarbital (oxidation), nicotine (N-acetylation),
amphetamine (deamination) and thiopental (desulphuration).
Phase
II: conjugations. Again taking place mainly in the liver, these reactions link,
for example, a glucuronide to the parent molecule of the product of a Phase I
reaction. Products of conjugations have greater water solubility than their
parents compounds and are readily excreted through the kidneys. Examples of
compounds undergoing Phase II metabolism include morphine (glucuronidation),
sulphonamides (acetylation), catecholamines (sulphate conjugation) and
histamine (methylation).
Metabolomics: the study of the metabolites of specific cellular processes. The metabolome is a collective term all the metabolites including primary and secondary metabolites, hormones and other signalling molecules in an organism and so is indicative of the end products of its gene expression.
Nordström A, Lewensohn R. Metabolomics: Moving to the Clinic. J Neuroimmune Pharmacol (2009) Apr 28
Metabotropic receptors: one of the major classifications of neurotransmitter receptors
(the other being inotropic). Metabotropic receptors are monomeric
proteins with seven transmembrane domains indirectly linked to ion-channels on
the cell plasma membrane via a signal transduction mechanism. This class of
receptor includes receptors for metabotropic glutamate receptors,
muscarinic receptors, GABAB receptors, most serotonin
receptors, catecholamine receptors, histamine receptors and neuropeptide
receptors. Activation of these receptors can both open and close ion
channels.
Metalloproteases
(matrix metalloproteases, MMP): also known as matrixins,
a family of about 20 enzymes which bind metals such as zinc and calcium in the
active site and which are proteases. They play important roles in tumour
metastasis, embryonic development, wound healing and matrix degradation. The
particularly affect tissue remodelling where collagen and proteoglycans are
present and are important targets for drugs being developed to inhibit
metastasis and connective tissue disorders.
Metalloprotease
inhibitors: compounds which inhibit the destructive effects of
metalloproteases on the extracellular matrix and which are being developed to
treat inflammation, connective tissue disease and to inhibit metastasis.
Examples include Ro32-3555 (Trocade), a collagenase selective inhibitor.
Metanephrine: a metabolite of adrenaline (epinephrine) and usually found in the
blood when there is phaeochromocytoma (a usually benign tumour of the adrenal
medulla which secretes catecholamines) present.
Metastasis: a process where tumour cells are released or break off from a
primary tumour mass, pass through the body in the blood or lymphatic tissue and
then establish themselves in a secondary site and grow like the primary tumour.
Tumours developing in this way can be as lethal as primary tumours.
Metastasis
inhibitor: compounds which inhibit the spread and establishment of
metastatic tumours in parts of the body other than that in which the primary
tumour is present. Metastasis inhibitors act by a variety of mechanisms including
inhibition of attachment of metastatic cells for example by integrin inhibitors
and cimetidine which inhibits the expression of E-selectin on the surface of
endothelial cells, proteolysis of the matrix membrane for example by
collagenase modulators and inhibition of metastatic growth for example by interleukin
antagonists or TGF-β antagonists.
Metformin: a biguanide hypoglycaemic compound used clinically to
treat diabetes. It inhibits gluconeogenesis and increases peripheral
utilization of glucose. It only works in the presence of insulin so requires
the presence of some functional β-cells in the islets of Langerhans in the
pancreas.
Methacholine:
a muscarinic receptor agonist similar in structure to
acetylcholine but with a methyl group in the β position of choline. It is a weak nicotinic
receptor agonist too and is hydrolysed by acetylcholinesterase
although more slowly than acetylcholine. It has no clinical uses in humans.
Methadone: a synthetic opioid agonist used clinically to treat opioid
dependence, severe pain and cough in terminal disease. It is structurally and
pharmacologically similar to morphine but longer acting. Its use in the
treatment of opioid dependence relies on its morphine-like effects but it shows
little euphoric effect.
Methamphetamine: a neurotoxin and an addictive stimulant drug which is
chemically related to amphetamine but which has more potent effect on
the central nervous system. Methamphetamine increases energy (it is a locomotor
stimulant) and alertness levels and decreases appetite and, like amphetamine,
has anorectic actions (ie, it promotes weight loss due to decreased food
intake).
Methamphetamine
is a drug of abuse and is otherwise known as speed, meth and chalk and
methamphetamine hydrochloride (which looks like ice in its crystal form) is
known as ice, crystal, glass and tina.
Methamphetamine-
induced
behavioral sensitization: an animal model used to
determine vulnerability of relapse of schizophrenia. In this model, repeated
administration of low doses of methamphetamine (or a similar CNS
stimulant such as amphetamine) to rodents causes progressive augmentation of
locomotor activity and this is referred to as behavioral sensitization.
Methamphetamine-
induced
hyperkinesia: a form of methamphetamine-induced motor disturbance
in which repeated administration of low doses of methamphetamine lead to
hyperkinesia. It has been used as an animal model to test drugs.
Methamphetamine-
induced
place preference: also known as
methamphetamine-induced conditioned place preference, an animal model in which
repeated administration of low doses of methamphetamine cause a
dose-dependent place preference.
Methapyrilene: an antihistamine found in cold and flu remedies and used
to treat allergies.It is also known to be a hepatotoxicant and a nongenotoxic
hepatocarcinogen used as a pharmacological tool to induce lived tumors
and liver damage.
Methaqualone:
an addictive, sedative hypnotic once used as a hypnotic to
treat insomnia. It is a drug of abuse. It was marketed in 1965 in the US under
the name Quaalude.
Methicillin: a semisynthetic penicillin and narrow-spectrum β-lactam
antibiotic used clinically to treat bacterial infections. It is resistant to
β-lactamases (also known as penicillinases) but resistance to it by
organisms such Staphylococcus aureus is a clinical problem so is not a
drug of choice.
Methicillin-
resistant
coagulase negative staphylococci (MRCNS):
strains of staphylococci which have become resistant to the antibiotic effects
of methicillin largely because they produce a penicillin-binding protein
which neutralizes the effects of methicillin. MRCNS is found in humans,
livestock and companion animals and has limited the use of methicillin as an
antibiotic.
Methicillin-
resistant
staphylococcus aureus (MRSA): a strain of Staphylococcus
aureus which has become resistant to the effect of methicillin due to the
production of altered penicillin-binding protein following the acquisition of
the mecA gene. This binding protein cannot bind β-lactams and they have no
effect on cell wall synthesis. MRSA emerged as far back as 1961 in the UK and
has caused many deaths worldwide since.
Methimazole: 1-methylimidazole-2-thiol, a thioureylene and antithyroid drug used clinically to treat Grave's disease (a form of hyperthyroidism). Methimazole
acts by inhibiting the synthesis of thyroid hormone probably by inhibiting the
iodination of tyrosyl residues in thyroglobulin and may competitively inhibit
thyroperoxidase-catalysed oxidation by acting as a substrate for this enzyme.
Methoctramine: a cardioselective M2 muscarinic receptor antagonist
used as a pharmacological tool. It directly inhibits the high
affinity GTPase activity of G proteins and it may improve memory.
Methohexital:
a barbiturate derivative used as a short-acting, rapid onset
sedative for anaesthesia. Like other barbiturates, it binds to a distinct site
which is associated with GABAA receptors.
Methonium
compounds: compounds containing polymethylene
bis-trimethylammonium cations which are generally ganglionic blockers and
depolarizing muscle relaxants. Examples include decamethonium.
Methotrexate:
previously known as amethopterin, a folic acid analogue, an anticancer
and antimetabolite inhibitor of dihydrofolate reductase (an enzyme
essential in DNA synthesis) used clinically as maintenance therapy for
childhood acute lymphoblastic leukaemia and for choriocarcinoma, non-Hodgkin's
lymphoma and a number of other solid tumours. It is also used in uncontrolled
psoriasis and in moderate to severe active rheumatoid arthritis. Methotrexate
is used in cats and dogs to treat lymphomas, carcinomas, sarcomas and
transmissible venereal tumours.
It
competitively and reversibly inhibits DNA synthesis because it is similar in
structure to folic acid which is the natural substrates for dihydrofolate
reductase. It prevents the conversion of folic acid to dihydrofolate and then
to tetrahydrofolate. (Tetrahydrofolate is normally then converted to
N5,N10-methylenetetrahydrofolate
which acts as a methyl group donor in various chemical pathways including the
synthesis of deoxythymidine monophosphate which is required in the synthesis of
thymidine.) Methotrexate is most effective in S phase of the cell cycle when
purines, pyrimidines and DNA are being actively synthesized in the cell.

Methoxamine:
a non-selective α1-adrenoceptor agonist
which causes a rise in blood pressure by vasoconstriction. It has been used to
treat hypotension.
5-Methoxy-N-
cyclopropanoyltryptamine: a potent melatonin receptor agonist. It is used as a
pharmacological
tool to investigate melatonin receptor subtypes.
Methoxyflurane:
a halogenated ether and potent inhalational anaesthetic used which
was once used for surgery but which is no longer used in humans. It has been
used in veterinary medicine since about 1960 and is still used as an
anaesthetic in cats and dogs usually as a maintenance anaesthetic after
induction of anaesthesia by, for example, pentobarbital.
N-methyl-D-
aspartate
(NMDA): an endogenous glutamate analogue and natural agonist of N-methyl-D-
aspartate
receptors.
N-methyl-D-
aspartate
receptors (NMDAR): a class of endogenous
ionotropic glutamate receptor which are sensitive to N-methyl-D-aspartate,
glutamate and glycine (which acts as a co-agonist at NMDA
receptor sites). They are important in excitotoxicity and neuronal plasticity
in the brain.
These
receptors are composed of NR1 and NR2 subunits and the glutamate binding domain
is formed at the junction of NR1 and NR2 subunits. The glycine binding site is
on NR1 an glycine binding is essential for the function of these receptors.
Activation of NMDA receptors causes the opening of an ion channel without
selectivity for cations and allows the flow of Na+, K+
and (to a lesser extent) Ca2+ ions across neuronal membranes.
Danysz
and Parsons. Glycine and N-Methyl-D-Aspartate Receptors: Physiological
Significance and Possible Therapeutic Applications. Pharmacological reviews.
(1988) 50, Issue 4; 597-664
http://pharmrev.aspetjournals.org/cgi/content/full/50/4/597
N-methyl-D-
aspartate
receptor agonists: compounds which activate NMDA
receptors, a process which normally requires the binding of glutamate and
glycine to the receptor. Examples include N-methyl-D-aspartate and
homoquinolinic acid.
N-methyl-D-
aspartate
receptor antagonists: compounds which block NMDA
receptors and so inhibit . Examples include ketamine, dextromethorphan, amantadine
and phencyclidine, MK-801and memantine (which is used clinically to
treat moderate to severs Alzheimer's disease).
NMDA
receptor glycine site antagonists: compounds which
specifically block the glycine binding site of the NMDA receptor. Examples
include L-701,324, L-689,560 and GV96771A. They may be of use in the treatment
of Parkinson's disease.
Methylazoxymethanolacetate
(MAMA): a short-acting, anti-mitotic which has been used as a pharmacological
tool as it is a potent carcinogen and neurotoxin. It inhibits hepatic DNA,
RNA, and protein synthesis.
3-Methylcholanthrene:
a carcinogen and pharmacological tool used to study
the effects of anticancer compounds.
Methyldopa:
a catecholamine (3,4-dihydroxyphenyl)-2-methyalanine)
analogue of levodopa.. It is an α-2 adrenergic agonist which
has both central and peripheral nervous effects. It is used clinically as an
antihypertensive agent where it produces its effects centrally.
Methyldopa
is taken up by adrenergic neurons and converted by dopa decarboxylase then
dopamine β-monooxygenase to α-methylnoradrenaline which is a false
transmitter. This compound accumulates and displaces noradrenaline from
storage vesicles. It is released along with noradrenaline is normal neuronal
activity but is less potent as a transmitter postsynaptically but does activate
presynaptic α2 adrenoceptors leading to feedback
inhibition and lower transmitter release.
Methylergonovine: also known as ergometrine and methergine, a semi-synthetic ergot
alkaloid which is used to prevent or treat bleeding from the uterus
following childbirth or abortion due to its vasoconstrictor actions. It
also has effects similar to LSD to which it is structurally related when given
at higher doses than used therapeutically.
3-Methylfentanyl:
also known as China White, a designer drug (ie, one which is for
recreational use but which is a derivative of an approved drug or an illegal
drug so as to circumvent existing legal restrictions or increase activity or
both). It is a potent narcotic analgesic and the cis-isomer is approximately
1000 or more times more potent than morphine.
N-Methylnitrosourea
(MNU): a carcinogen and pharmacological tool used to
induce experimental tumours. Typically, intrarectal doses of 2mg
N-methylnitrosourea dissolved in 0.5ml water given three times a week for 4-5
weeks will induce colon cancer.
α-Methyltyrosine: a tyrosine analogue and an inhibitor of tyrosine 3-monooxygenase
and which inhibits the synthesis of all catecholamines. It has been used
to control excessive sympathetic stimulation caused by adrenaline and
noradrenaline released from phaeochromocytoma (a largely benign tumour of the
adrenal medulla which causes the release of adrenaline and noradrenaline into
the blood).
5-Methylurapidil: a selective α1A-adrenoceptor antagonist
used as a pharmacological tool to investigate adrenoceptor subtypes.
Urapidil has been used as an antihypertensive as it is a vasodilator.
Methyllycaconitine: a toxin purified from the seeds of Delphinium brownii and
a selective and potent antagonist of α7 neuronal nicotine receptors.
It is used as a pharmacological tool to investigate nicotinic receptor
subtypes.
Methylphenidate: an amphetamine-like CNS stimulant used clinically to treat
attention deficit hyperactivity disorder (ADHD). It has also been used to treat
traumatic brain injury, daytime sleepiness and chronic fatigue syndrome.
Methylphenidate is a dopamine reuptake inhibitor although the exact mechanism
of its actions in ADHD are unclear. See http://en.wikipedia.org/wiki/Methylphenidate
Methysergide:
a synthetic ergot alkaloid and LSD-like drug used
clinically to prevent severe recurrent migraine, cluster headaches and other
vascular headaches in patients who do not respond to other treatment. It is not
a drug of choice due to its side effects. It
is structurally related to the oxytocic agent methylergonovine
and is a more potent peripheral serotonin receptor antagonist than other
ergot alkaloids. Methysergide blocks 5-HT receptors in the brain and is a weak
vasoconstrictor.
Metirosine:
a compound (α-methyl-L-tyrosine) which inhibits tyrosine
carboxylase and prevents the conversion of tyrosine to dopa.
Treatment of neurones with this compound will lead to a depletion of
transmitter stores in noradrenergic and dopaminergic neurones and chromaffin cells.
It is used clinically in the pre-operative management of phaeochromocytoma and
in the long term to treat this disorders where surgery is unsuitable.
Metoclopramide: an anti-emetic drug used to clinically to treat nausea and
vomiting particularly those related to gastrointestinal diseases and those
caused by treatment cytotoxic anticancer drugs or radiotherapy. It is also used
to relieve the symptoms of nausea associated with migraine attacks.
Metoclopramide
is a dopamine receptor antagonist which exerts its actions in the
chemoreceptor trigger zone in the area postrema in the brain. It also directly
stimulates the motility of the stomach and intestines. This increases the
gastric emptying rate but without a concomitant increase in gastric acid secretion.
Metoclopramide is also used clinically to treat non-ulcer dyspepsia and in the
treatment of gastro-oesophageal reflux disease (GERD).
Metoprolol:
a cardioselective but not cardiospecific β1-adrenoceptor
antagonist used clinically to treat hypertension, angina and arrhythmias.
Metrazole:
a non-competitive GABA antagonist which acts as a CNS
stimulant of respiration. It can induce seizures in small animals and has been
used as a pharmacological tool in the anti-metrazole seizure (threshold) test
to evaluate the effects of anticonvulsants.
Metronidazole:
a nitroimidazole amoebicidal compound used clinically to
treat amoebal infections in humans and small animals. It is effective against Entamoeba
histolytica, giardiasis such as that caused by Giardia lamblia,
trichomoniasis such as that caused by Trichomonas vaginalis, ulcerative
gingivitis and Crohn's disease. It is the drug of choice in the treatment of
acute invasive amoebic dysentery. Metronidazole appears to act against
trophozoites of Entamoeba by damaging the DNA of the infective organism
by the production of toxic oxygen products of this drug by the parasite itself.Examples of nitroimidazole amoebicidals are shown in the figure below with the nitroimidazole moiety shown in blue.

Metyrapone:
a competitive inhibitor of 11β-hydroxylation (it is an 11
β-hydroxylase inhibitor) in the adrenal cortex and so inhibits the
production of cortisol and to a lesser extent aldosterone. This decrease in
cortisol leads to an increase in the synthesis of adrenocorticotrophic
hormone (ACTH) which leads to an increase in the production of cortisol
precursors. Metyrapone is used to evaluate the function of the anterior
pituitary and to treat Cushing's syndrome (an endocrine disorder caused by high
levels of cortisol in the blood).
Meyer-Overton
hypothesis: a hypothesis about anaesthetics which says
that the minimum alveolar concentration (MAC) of a volatile substance is
inversely proportional to its lipid solubility. The more lipid soluble the
anaesthetic, the higher the potency and the lower the MAC.
MgTX:
margatoxin
Mianserin: an atypical and tricyclic antidepressant.used clinically
to treat depressive illness particularly where sedation is required. Mianserin
blocks α2-adrenoreceptors, 5-HT2 serotonin
receptors and H1 histamine receptors. It does not affect
monoamine reuptake. It may increase noradrenaline release by blocking α2
adrenoceptors on adrenergic neurones.
MIC: minimum inhibitory concentration.
Michaelis-Menten
equation: also known as the Henri-Michaelis-Menten equation, one of the
best and earliest known theoretical descriptions of enzyme reaction kinetics.
Miconazole:
an azole and antifungal compound used topically and
orally to treat fungal infections such as oral and intestinal infections and to
treat wounds infected with fungi. Azoles including miconazole, ketoconazole,
fluconazole and itraconazole inhibit fungal P450 enzymes which are responsible
for the synthesis of ergosterol, the main sterol and an important structural
component of fungal cell walls. The azoles inhibit fungal replication.
Microfilaricide: compounds which kill microfilaria, the immature forms heartworms
which circulate in the blood. In humans, filarial infections can cause river
blindness (onchocerciasis) and elephantiasis (caused by the nematode worms Wuchereria
bancrofti and Brugia malayi in the lymphatic system). These can be
treated with diethylcarbamazine, albendazole and ivermectin.
Examples
of veterinary microfilaricides include dithiazanine iodide, ivermectin,
levamisole, milbemycin and fenthion. Macrofilaricides are drugs which
kill adult filarial worms (macrofilariae). An example of a veterinary
macrofilaricide is moxidectin.
Micronucleus
test: an in vivo test to determine if a compound has clastogenic
effects (ie, it causes chromosome breaks) or impairs mitosis, spindle fibre
function or cytokinesis. These tests are usually carried out using mice and the
effects of these compounds are observed by histological examination of
erythrocyte stem cells taken from treated animals. Micronuclei in these cells
indicates that chromosomes or their fragments have failed to migrate properly
in anaphase.
Micropig®: the registered trade name of a small, docile pig originating in
the Yucatan peninsula in Mexico. This predominantly hairless, slate grey to
black pig is used as an alternative to dogs and primates in cardiovascular
studies since body weight does not usually exceed about 16-18kg at one year of
age. It is therefore relatively economical to rear. It
does show some cardiac anomalies such as arrhythmias compared to dogs and
primates but is otherwise a suitable small animal for cardiovascular studies. Hairless
micropigs have been used to model skin disease.
Microsomal
triglyceride transfer protein (MTTP): a
heterodimeric lipid transfer protein which catalyzes the transport of
triglycerides, cholesteryl esters and phosphatidylcholine between membranes.
MTTP is a target for the control of lipid metabolism.
Microsomal
triglyceride transfer protein (MTTP) inhibitors:
compounds which inhibit MTTP and so decrease blood triglyceride levels. They
are being developed to treat hyperlipidemia and examples include JTT-130,
implitapide and CP-346086.
Microsomes:
small enclosed vesicles about 100nm in diameter which are membrane
fragments formed form the endoplasmic reticulum when cells are homogenized.
Midkine: a basic protein strongly expressed in midgestation which promotes
the survival and migration of various cells but also promotes growth of
fibroblasts and tumour cells, it promotes the survival of embryonic neurons,
promotes the migration fo neurons and neutrophils and promotes angiogenesis in
tumours. See http://www.midkine.org/index-e.html
Mifepristone
(RU486): an anti-progestogenic steroid and partial progesterone agonist but
which inhibits the actions of its progestogen. It sensitizes the myometrium to
prostaglandin-induced contractions and it dilates and softens the cervix. It is
used clinically in combination with vaginal administration of the prostaglandin
gemeprost (about 48 hours later) for medical termination of pregnancy.
Mahajan
DK, London SN. Mifepristone (RU486): a review. Fertil Steril (1997) Dec
68(6):967-76
Migraine-abortive
agent: compounds which stop acute migraine attacks. Examples include
tolfenamic acid, triptans (5-HT1 serotonin agonists such as
almotriptan, sumatriptan and zolmitriptan) and ergotamine derivatives eg,
ergotamine tartrate although these are rarely used now.
Mimetic:
a substance that mimics or imitates the actions of another
substance which usually has a well established physiological function. Examples
include sympathomimetics and peptidomimetics.
Mineralocorticoids: corticosteroids produced by the adrenal cortex which are involved
with Na+ and K+ balance and also in water balance within
the body. The most important is aldosterone which causes Na+ (and
therefore water) retention by the kidneys and K+ excretion.
Minimum
alveolar concentration (MAC): a measure of the potency of an
inhalational anaesthetic which is the alveolar concentration that prevents
gross purposeful movement in 50% of patients or animals treated with it in
response to a standardized and painful stimulus. See Meyer-Overton
hypothesis.
Minimum
inhibitory concentration (MIC): the minimum
concentration of an antimicrobial compound in a given culture medium which
inhibits the growth of the bacterium. The MIC of a particular antibiotic is
given in mg/L and is an indication of susceptibility of bacteria and fungi to
microbistatics and microbicides.
Minor
tranquilizers: also known as anxiolytics, ataractics,
neuroleptics and sedatives, drugs which are used to treat anxiety, to induce
calm and treat sleep disorders but not psychoses such as schizophrenia for
which major tranquilizers are used. Several types of compound are grouped into
minor tranquilizers and include benzodiazepines, 5-HT1A serotonin
receptor agonists, barbiturates, β-adrenoceptor antagonists and
other drugs such as choral hydrate, meprobromate and paraldehyde.
Minoxidil: a vasodilator used clinically to treat severe hypertension which
is resistant to other drugs. It causes an increase in cardiac output and fluid
retention so is usually used in conjunction with a diuretic and a β-
blocker. When
applied topically, minoxidil can promote hair growth and is used to treat
male-pattern baldness. The mechanism by which it stimulates hair growth is
unclear although it may be due to vasodilation and improved blood flow around
the hair follicles.
Miotics: drugs which cause constriction of the pupil (miosis) and
increased drainage of the aqueous fluid in the eye. They are used to treat
glaucoma because they can open drainage channels in the trabecular meshwork
closure of which is caused by contraction or spasm of the ciliary muscles.
Examples of miotics include parasympathomimetics and cholinergic
agonists such as acetylcholine chloride, pilocarpine and
carbachol.
Misoprostol: a synthetic prostaglandin analogue which has gastroprotectant and
antisecretory properties and which is used clinically to treat benign gastric
anc duodenal ulcers and NSAID-associated ulcers. It is also used in
formulations with diclofenac or naproxen.
Misoprostol
is also used by oral or vaginal administration to induce abortion often with
mifepristone.
In this case, mifepristone blocks the effects of progesterone which is needed
to maintain pregnancy, the uterine lining begins to shed and the cervix begins
to soften. A follow up dose of misoprostol causes the uterus to contract and
the foetus is usually expelled within 6 to 8 hours.
Miticides:
also known as acaricides.
Mitogen-activated
protein kinase (MAP kinase): see MAP kinase.
Mitomycins:
a family of antibiotic and anticancer compounds
(they are cytotoxic antibiotics) based around a pyrro[1,2-a]indole nucleus and
produced by some strains of Streptomyces such as Streptomyces
verticillatus and Streptomyces caespitosus. They were discovered in
the 1950s (mitomycins A and B) and showed potent antibacterial activity,
moderate antitumor actions but were quite toxic. Mitomycin C was isolated from
Streptomyces
caespitosus in 1958.
Mitomycin
C is used clinically in the treatment of upper gastrointestinal, bladder and
breast cancer. It is activated in vivo to a bifunctional or
trufunctional compound which binds to (preferably) the guanine and cytosine
moieties in DNA leading to crosslinking and inhibition of DNA synthesis and
function.
Mitosis
inhibitors: compounds which inhibit mitosis (non-sex
cell division) and which are used to treat tumours. Examples include vinca
alkaloids such as vincristine and vinblastine. They bind to
tubulin protein in the mitotic spindle and block its polymerization to form
microtubules so blocking cell division in metaphase.
MK
912: an α2-adrenoceptor antagonist used as a
pharmacological
tool in the study of adrenoceptor subtypes.
MMOA: multiple mechanisms of action
MMP:
matrix metalloprotease.
Mofetil: a 2-morpholinoethyl ester. Examples include mycophenolate mofetil used as an immunosuppressant.
Molal: a one molal solution contains one mole of substance in
1000g of solvent.
Molarity
(M): a measure of the concentration of a solution of drug or other
substance. A 1M (one molar) solution contains 1 mole (ie, Avogadro's number,
6.022 x 1023, of molecules) of a drug in 1000mL of solution.
Normal
(N) has been used as a measure of the strength of acids and bases but this term
is outdated and molarity is preferred.
Mongolian
gerbil: a commercially available laboratory animal originally from a
litter caught in Mongolia in the 1930s. These animals are subject to a variety
of spontaneous conditions such as epileptiform seizures, hyperadrenocorticism,
diabetes, obesity, periodontal disease and dental caries.
Monoamines: small organic molecule containing both a carboxyl group and an
amino group bonded to the same carbon atom. They are abundant in humans and
include (the biogenic monoamines) adrenaline, noradrenaline,
histamine,
serotonin and dopamine.
Monoamine
oxidase (MAO): officially known as amine oxidase (EC 1.4.3.4), an enzyme which catalyze the
oxidative deamination of catecholamines to form their aldehydes which (in the
periphery) are further dehydrogenated by aldehyde dehydrogenase to form
carboxylic acids or alcohols. MAO is bound to mitochondrial membranes and is
abundant in noradrenergic nerve terminals and in other locations such as the
liver and intestinal epithelium. MAO also oxidizes dopamine and 5-HT.
There
are two known isozymes of MAO, MAO-A and MAO-B and they differ in their
substrate preference. MAO-A prefers 5-HT and noradrenaline, whereas MAO-B is
more common in human platelets and prefers more hydrophobic amines such as
phenethylamine and benzylamine.
Monoamine
oxidase inhibitor (MAOI): compounds which inhibit the
actions of monoamine oxidases and so increase central and peripheral
levels of catecholamines. They were introduced originally for the treatment of
depressive illness. The first MAOI introduced were non-selective for MAO-A and
MAO-B. The main problem with MAO-A inhibition is that dietary tyramine was not
oxidatlvely deaminated by this enzyme in the gut allowing tyramine to enter the
bloodstream. Tyramine is an indirectly acting sympathomimetic amine
which has pressor effects in the blood vessels leading to the cheese
reaction (ie, marked hypertension due to vasoconstriction). More
MAO-B-selective compounds are used clinically to treat Parkinson's disease.
Examples include selegiline (an irreversible suicide inhibitor of MAO-B)
which is used alone or in combination with levodopa. Other MAO-B
selective inhibitors include rasagiline, lazabemide and mofegiline.
Older
1st generation non-selective (and irreversible) MAOI include
pargyline and tranylcypromine, phenelzine and isocarboxazid which are still
used clinically to treat depressive illness. The 2nd generation
MAO-I which are irreversible but which show a preference for inhibition of
MAO-B and include selegiline. Third generation MAOI include reversible
inhibitors of monoamine oxidase (RIMA) such as moclobemide (an inhibitor of
MAO-A but causing less pressor effects of tyramine). Moclobemide is used clinically
to treat depressive illness and social phobia.
Monoamine
oxidase inhibitors are also used to treat demodectic, sarcoptic and notoedric
mange (a skin disease in animals caused by mites) in dogs and cats. Examples
include amitraz which disrupts the mite nervous system.
Monoamine
reuptake inhibitors: compounds which inhibit the
reuptake of monoamines and so potentiate the effects of monoamines on their
receptors. They include dopamine reuptake inhibitors such as brasofensine,
noradrenaline (specific) reuptake inhibitors (NRSI) such as amoxapine and
maprotilene, (selective) serotonin reuptake inhibitors (SSRI) such as
fluoxetine and sertraline, serotonin-noradrenaline reuptake inhibitors (SNRI)
such as duloxetine and milnacipran and serotonin-noradrenaline-dopamine
reuptake inhibitors.
Monoamine
theory of depression: the idea that depressive
illness arises from a deficit in noradrenaline and/or serotoninactivity in the
brain and that antidepressants work by normalizing this deficit. It is based of
the observation that monoamine oxidase inhibitors and tricyclic antidepressants
both increase in the activity of monoamines in the brain and improve the
symptoms of depression.
Monocarboxylate
transporters: membrane transport proteins for
monocarboxylate compounds such as pyruvate and lactate. They play an important
role in energy metabolism and metabolite homeostasis.
Monochloramine: an ulcerogenic chloride of ammonia (NH2Cl) used
to induce (usually gastric) ulcers.
Monoclonal
antibody: an antibody which has been derived from a single
antibody-producing clone, ie all the antibodies produced by this clone are
identical and have identical reactivity. These clones are actually myeloma
cells which have been fused to antigen-sensitized spleen cells. The myeloma cells
give the fused cell longevity and the spleen cell produces antibodies.
Monoclonal
antibodies have a broad range of applications particularly in diagnostic
medicine and therapy. Examples of MAb used in therapy include daclizumab and
basiliximab in the treatment of transplant rejection, rituximab and bevacizumab
in the treatment of cancer and infliximab and omalizumab in the treatment of
inflammation. See http://en.wikipedia.org/wiki/Monoclonal_antibody
Monocrotaline:
a pyrrolizidine alkaloid and a toxic plant constituent used to
induce pulmonary hypertension in animal models. It causes pulmonary artery
hypertension, right ventricular hypertrophy and pathological changes in the
pulmonary vasculature. It has been used as a pharmacological tool to induce
pulmonary artery hypertension and cardiac hypertrophy. It mechanism may be
based on increasing oxidants, circulating levels of catecholamines and
haemodynamic load or by inducing hypoxia in cardiac tissue.
Monolactams: also referred to as monobactams and monocyclic β-lactams, a
class of β-lactams having only one ring in the structure and not the usual
bicyclic structure associated with β-lactams. Examples include aztreonam.
L-NG-
Monomethyl
arginine (LNMMA): a competitive nitric oxide
synthase (NOS) inhibitor and an analogue of L-arginine. It inhibits NO
production.
Monosodium
glutamate-treated mouse: a mouse model of obesity and
endocrinological dysfunction caused by the neurotoxic effects of monosodium
glutamate (MSG) in the hypothalamus. Neonatal administration of monosodium
glutamate permanently damages the neurons in the hypothalamic arcuate nucleus
which contain growth hormone releasing hormone and prolactin-secretion
inhibiting dopamine neuron cell bodies. These animals show obesity and stunted
growth due to decreases in growth hormone levels.
Montelukast: a leukotriene receptor antagonist used to treat asthma and
allergies. It blocks the actions of leukotriene D4 on cysteinyl leukotriene
receptor CysLT1 receptors in the bronchi causing bronchodilation. It
is one of the 'leukast' family of anti-asthma drugs which includes pranlukast,
zafirlukast, iralukast and cinalukast.
Mood
stabilizers: also known as antimanics.
Morning-after
pill: also knows as the post-coital pill, a form of contragestational
agent which can prevent pregnancy which can be taken within 72 hrs of
unprotected intercourse to lessen the risk of conception. It is a pill
containing levonorgestrel and increases the thickness of the natural mucus in
the cervix making it difficult for sperm to cross from the vagina into the
uterus. It also changes the lining of the uterus preventing it from being
prepared for a fertilised egg. The
morning after pill used to comprise two tablets which had to be taken twelve
hours apart.
Morphinans:
a family of morphine-like compounds which differ
structurally from morphine with the absence the oxygen bridge. Morphinans are
similar to morphine in the analgesic actions although they are often more
potent and longer acting.

Morphine: a narcotic opioid analgesic used clinically as an
antimotility agent (ie, it slows or halts peristalsis) to treat uncomplicated
acute diarrhoea, to treat cough (it is an antitussive) and to treat moderate to
severe pain of visceral origin eg, following surgery or that associated with
cancer (often in palliative care). Morphine is an agonist of μ- opioid
receptors and this receptor subtype is thought to be responsible for the
analgesic actions of opioids
Morris
hidden platform maze: a device used to test place
learning and memory devised by Richard Morris in the mid 1980s. This device
comprises a tank filled with water and a submerged (hidden) platform. The
animal, usually a rat, is allowed to learn where the platform is and this
method can be used to determine the effects of drugs on placed learning and
memory.
Morris R. Developments of a water-maze procedure for studying
spatial learning in the rat. J Neurosci Methods (1984) 11(1):47-60
See http://www.watermaze.org
Motilides: macrolides with direct contracting effects on the small
intestine.
Itoh Z,
Omura S. Motilide, a New Family of Macrolide Compounds Mimicing Motilin. Dig
Dis Sci (1987) 32: 915
Motilin:
a 22 amino acid gastroprokinetic polypeptide hormone
produced and secreted from the endocrinocytes in the mucosa of the proximal
small intestine. It plays an important role in the initiation of phase III
activity of the interdigestive migrating contractions (IMC) in dogs and man and
increases the production of pepsin.
In
humans, the precursor of motilin consists of 115 amino acids including a 25
amino acid signal peptide and a 66 amino acid carboxy-terminal
motilin-associated peptide (MAP). Motilin is abundant in the duodenum where it
appears to act directly on motilin receptors located on gastrointestinal smooth
muscle cells causing an increase in gut contractions and an increase in gastric
emptying. Motilin receptors are also thought to be present in the nervous
system.
Motilin
receptor: a G protein-coupled receptor present in the gut to which motilin
binds to cause increases gut activity.
Feighner
SD et al. Receptor for motilin identified in the human gastrointestinal
system. Science (1999) Vol. 284 No. 5423:2184 - 2188
Motilin
receptor agonists: compounds which agonise motilin
receptors and so increase gastric emptying rate. They are being developed
to treat gastroparesis and gastroesophageal reflux disease (GERD). Examples
include erythromycin A, the erythromycin derivative EM-523, GM611, KOS-2187 and
ABT-229. They greatly increase gastrointestinal motor activity.
Motilin
receptor antagonists: compounds which block the
effects of motilin at its receptor site. Motilin antagonists are being developed
for the treatment of irritable bowel syndrome (IBS) and functional dyspepsia.
Slowing of the gut appears to inhibit the diarrhoea-like symptoms of IBS.
Examples of motilin receptor antagonists include TZP-201, ANQ-11125, RWJ-68023.
Moxonidine:
a second generation, centrally-acting antihypertensive which act
as a selective I1 imidazoline receptor agonist and an
α2-adrenoceptor
agonist in the brainstem sympathetic nuclei. It is used clinically to treat
mild to moderate essential hypertension and is similar to clonidine.
Mouse:
a commonly used animal in research because it is easy to rear and
inexpensive. A good source of genetic information about mice can be found at
Mouse Genome Informatics (http://www.informatics.jax.org/).
Mouse
ear-scratch reflex: also known as the scratch
reflex, ear-scratch response and scratch-reflex stereotypy, a reflex in which
the mouse scratches the head and area around the ear with the hind paw. It is
observed after the administration of some types of hallucinogens such as
the phenylisopropylamine, DOM and mescaline. Indolealkylamine
hallucinogens, however, such as psilocybin do not illicit this reflex
and LSD is essentially inactive. This reflex has been used to investigate the
effects of some types of hallucinogens and psychoactive drugs in mice.
MPA:
mycophenolic acid
MPPP: a designer drug (1-methyl-4-phenyl-4-
proprionoxypiperidine)
used for its opioid-like actions. (see MTPT).
MPTP: a neurotoxin (N-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine) which is structurally related to pethidine and which is used
experimentally in models of Parkinson's disease. This compound appeared as a
contaminant of MPPP which was a designer drug of abuse used in
California in the early 1980s due to its opioid activity. MPTP is neurotoxic
and is known to cause irreversible damage to dopaminergic fibers in the
nigrostriatal
pathway.
MRCNS:
methicillin-resistant coagulase negative stsphylococci
MRSA:
methicillin-resistant staphylococcus aureus
MRT: mean residence time
MSA: membrane stabilizing action
MT3 and
MT7: toxins present in the venom of green mamba (Dendroaspis
augusticeps). They are non-subtype selective muscarinic receptor
antagonists.
MTTP:
microsomal triglyceride transfer protein
MTT
assay: a colourimetric cell proliferation inhibition assay carried out to
determine the effect of compounds on cell proliferation such as in testing the
effects of antimicrobial and anticancer drugs. MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) is yellow and is
oxidized to form purple formazan by mitochondrial reductases - the amount of
formazan formed being directly related the number of cells (the colour can be
measured spectroscopically). Antimicrobials and anticancer drugs decrease the
formation of formazan (as dead cells cannot convert MTT to formazan) compared
to untreated control cells (which can proliferate unimpaired).
Mosmann
T. Rapid colorimetric assay for cellular growth and survival: application to
proliferation and cytotoxicity assays. J Immunol Meth (1983) 65:55-63
MTX:
maurotoxin
Mucolytic:
a drug which lowers the viscosity of mucus making it easier to
expel from the airways. Mucolytics include agents that depolymerize the
mucopolysaccharide-protein fibres in mucus. These agents are commonly used in
the symptomatic treatment of coughs.
Multidrug
resistance (MDR): a process where microorganisms
and cells become resistant to the drug or drugs s being used to eradicate them
despite being sensitive to these drugs at the start of treatment. There
are several mechanisms by which cells can acquire multidrug resistance. Human
P-glycoprotein (also known as MDR1 which normally expels toxins from cells) and
the multidrug resistance-associated protein (MRP) both function as ATP-dependent
cellular efflux transporters for cytotoxic drugs in human multidrug resistant
cells. If they are overexpressed in tumours or cultured tissue cells, they
expel the cytotoxic drug leading to resistance to these drugs. MDR is a common
problem for the vinca alkaloids vincristine and vinblastine,
dactinomycin and anthracyclines.
Multimeric
receptors: receptors which are made up of more than one part. For example,
ionotropic glutamate receptors are multimeric assemblies of four or five
subunits and this is typified by GABAA receptors.
Multidrug transporter: also known as P-glycoprotein, a transporter mechanism which evolved to protect cells from xenobiotics and is found in the cell membrane. The transporter is normally found in several key places in the body, specifically the lining the digestive tract where it reduces absorption of toxic compounds in the diet, in the kidney and liver where it helps in the excretion of xenobiotics and in the cells lining the capillaries in the brain forming one line of defense in the blood-brain barrier. In cancer cells, this transporter is responsible for resistance to anticancer compounds but can account for drug resistance in a broad range of mammalian, bacterial and fungal cells.
Mizutani T et al. Genuine functions of P-glycoprotein (ABCB1). Curr Drug Metab. 2008 Feb;9(2):167-74
Murad,
Ferid (1936 - ): American pharmacologist who
shared the Nobel Prize for Physiology or Medicine in 1988 with Furchgott
and Ignarro 'for their discoveries concerning nitric oxide as a signaling molecule in the cardiovascular system'.
http://nobelprize.org/nobel_prizes/medicine/laureates/1998/murad-autobio.html
Muramyl
dipeptide (MDP): a nonspecific immunostimulant, the
smallest immunologically active unit in the wall of a gram negative bacteria
and an important component in its structure as it forms part of the
peptidoglycan molecule (chemically it is N-acetylmuramyl-L-Ala-D-Glu-NH2).
It is an immunostimulant which can enhance nonspecific resistance to infection.
Traub S et al. MDP and other muropeptides--direct and synergistic effects on the
immune system. J Endotoxin Res (2006), 12(2):69-85
Muricidal: relating to the killing of a rat or mouse and often applied to an
unusual form of aggressive behaviour where a rat will kill and may partly eat a
mouse.
Murine:
usually taken as relating to rats and mice (but includes animals
of the genus Muridae including rats, mice, gerbils and jirds).
Muropeptides: breakdown products of peptidoglycan from gram-positive and
gram-negative bacteria and which have immunostimulant actions.
Muscarine:
a toxic alkaloid obtained from
the mushroom Amanita muscaria and some other fungi. It is a potent and
selective mimic of acetylcholine at central muscarinic receptors.
It also stimulates the peripheral parasympathetic system to induce miosis,
vomiting, diarrhoea and bradycardia.
Muscarinic: relating to the actions of muscarine and the effects of compounds
in agonizing or antagonizing muscarinic cholinoceptors.
Muscarinic
receptors: also known as muscarinic cholinoceptor, membrane-bound
acetylcholine receptors present in most tissues of which five have so
far been identified, ie M1, M2, M3, M4
and M5. They are metabotropic receptors and use G proteins in their
signalling mechanism and have 7 transmembrane regions (in contrast to nicotinic
cholinoceptors which are ion-gated). The table below shows the main
classification of muscarinic receptors and some agonists and antagonists.
|
Subtype
|
M1
|
M2
|
M3
|
M4
|
M5
|
|
Location
|
Cortex,
hippocampus
|
Heart,
present
presynaptically
|
Endocrine
glands,
GI
tract
|
Neostriatum
|
Substantia
nigra
|
|
Action
mediated
|
excitatory
effects
|
cardiac
effects, eg vagal stimulation (slows the heart)
|
parasympathetic
stimulation, excitatory effects on glands and smooth muscle
|
|
|
|
Agonist
|
Areclidine
Oxotremorine
Pilocarpine
Xanomeline
CDD-
0097
Bethanecol
Alvameline
Cevimeline
Milameline
Sabcomeline
SR
46559A
Xanomeline
|
Areclidine
Oxotremorine
Pilocarpine
Bethanecol
Milameline
|
Areclidine
Oxotremorine
Pilocarpine
Bethanecol
|
Areclidine
Oxotremorine
Pilocarpine
Xanomeline
Bethanecol
|
Areclidine
Oxotremorine
Pilocarpine
Bethanecol
|
|
Antagonist
|
Pirenzepine
Scopolamine
(same as hyoscine)
Telenzepine
Atropine
Dicyclomine
|
AF-
DX116
AF-DX
384
(S)-(+)-
dimethidine
Scopolamine
(same as hyoscine)
Atropine
Darifenacin
SCH-
217443
SR
46559A
gallamine
|
pF-
HHSiD
4-DAMP
Scopolamine
(same as hyoscine)
Atropine
Hexahydrosiladifenol
|
Scopolamine
(same as hyoscine)
Tropicamide
Atropine
|
AF-DX
384
Scopolamine
(same as hyoscine)
Atropine
|
|
G
protein
|
Gαq/11
|
Gαi/o
|
Gαq/11
|
Gαi/o
|
Gαq/11
|
|
Intracellular
response
|
Phospholipase
Cβ
↑IP3
↑DAG
|
Adenylyl
cyclase inhibition
↓cAMP
|
Phospholipase
Cβ
|
Adenylyl
cyclase
inhibition
|
Phospholipase
Cβ
|
|
Uses
of agonists
|
bladder
and gastrointestinal hypotonia, glaucoma (eg carbachol and pilocarpine in
wide angle glaucoma), Alzheimer's disease and Sjogren syndrome (eg cevimeline
which is M1 specific), treatment of urinary incontinence (eg
bethanechol), miosis (eg acetylcholine)
|
|
Uses
of antagonists
|
adjunct
to anaesthesia (atropine reduces saliva secretion and causes
bronchodilation), anticholinesterase poisoning, bradycardia, gastrointestinal
hypermotility, irritable bowel syndrome, motion sickness, peptic ulcer (eg
selective M1 antagonist pirenzepine), used to induce mydriasis and
cycloplegia (tropicamide)
|
MP Caulfield and JM Birdsall.
International Union of Pharmacology. Classification of Muscarinic Acetylcholine
Receptors. Pharmacological Reviews. (1998) 50(2): 279-290
See http://pharmrev.aspetjournals.org/cgi/content/full/50/2/279.
Eglen
RM, Watson N. Selective muscarinic receptor agonists and antagonists. Pharmacol
Toxicol (1996) 78; 59-78
Muscarinic
receptor agonist: compounds which agonize
muscarinic receptors. They are used clinically for a range of disorders shown
in the table above.
Muscarinic
receptor antagonist: compounds which block
muscarinic receptors. Their uses are shown in the table above.
Muscarinic
toxins (MT): a family of peptides isolated from venom
of green mamba (Dendroaspis angusticeps) black mamba (Dendroaspis
polylepis). They fall into three groups, types A, B and C. Examples include
MT3, MTx1 and MTx7. Muscarinic
toxins show high affinity for muscarinic receptors and are used as
pharmacological
tool.
Muscimol:
also known as agarin, pantherine and pyroibotenic acid, a
psychoactive compounds (3-Hydroxy-5-aminomethylisoxazole) present in fly agaric
(a mushroom, Amanita muscaria) and the deathcap mushroom (Amanita
phalloides). It is the decarboxylation product of ibotenic acid and
it is a selective GABAA receptor agonist. It is used as a
pharmacological
tool to investigate these receptors.
Muscle
relaxants: a diverse group of compounds used to induce the relaxation of
smooth and skeletal muscles. There are broadly divided into five groups; 1)
Non-depolarizing (also known as competitive neuromuscular blocking agents) and
2) depolarizing muscle relaxants are used clinically in anaesthesia as they
relax the muscles of the trachea, diaphragm and abdomen. They also relax the
vocal cords to facilitate intubation. 3) Centrally acting muscle relaxants and
are used to treat chronic severe spasticity due to multiple sclerosis or
traumatic section of the spinal cord. 4) Compounds acting directly on muscle to
cause relaxation are used to treat chronic severe spasticity and malignant
hyperthermia. 5) Other compounds.
1)
Non-depolarizing muscle relaxants (ie the majority of these drugs) are also
known as competitive muscle relaxants and compete with acetylcholine for
nicotinic receptors in the muscle. This non-depolarizing group can be
subdivided into the aminosteroid group which includes pancuronium,
rocuronium, rapacuronium, pipecuronium and vecuronium and the benzylisoquinolinium
group which includes atracurium, cisatracurium (a stereoisomer of atracurium),
doxacurium and mivacurium. Other non-depolarizing compounds include gallamine,
alcuronium, metocurine and fazadinium. All these compounds tend to have an
intermediate to long duration of action and slow onset.
2)
Depolarizing muscle relaxants induce a prolonged depolarization of the endplate
of muscle fibres which leads to a loss of electrical excitability (hence the
term depolarizing). They are not metabolized by acetylcholinesterase in the
synaptic cleft so they remain in the cleft to continuously depolarize the end
plate. They show rapid onset and short duration of action. Examples include
suxamethonium, hexafluorenium and decamethonium.
The
above two types of muscle relaxants are also known as parasympatholytics (they
abolish parasympathetic effects on muscles) and are often classified by
their duration of action as ultra-short acting (<15 minutes, eg succinylcholine,
rapacuronium), short-acting (15-30 minutes, eg mivacurium), intermediate-acting
(30-60 minutes, eg atracurium, cisatracurium, rocuronium and vecuronium) and
long-acting (60-120 minutes or longer, eg pancuronium, gallamine, metocurine,
doxacurium and pipecuronium).
3)
Centrally acting muscle relaxants act via a central mechanism in the CNS and
are used to treat muscle spasms such as those associated with tetanus and
spasticity (characterized by hypertonicity which is an increase in normal
muscle tone and resistance to stretching) and chronic severe spasticity
associated with multiple sclerosis or traumatic spinal injury. They have
various mechanisms of action. For example, baclofen is a selective
presynaptic GABAB receptors agonist and it exerts its
antispastic effects mainly in the spinal cord. Baclofen inhibits mono- and
polysynaptic activation of motor neurons leading to a relaxation of muscle
tone. Mephenesin acts mainly on the spinal cord inhibiting polysynaptic
excitation of motor neurons. Guaifenesin
is a centrally acting muscle relaxant used in combination with thiobarbiturates
and ketamine in anaesthesia prior to surgery in horses, cattle and swine.
4)
Compounds acting directly on muscle. These include dantrolene and quinine and
musculotropic and neurotropic-musculotropic spasmolytics. Dantrolene
is used to treat chronic severe spasticity of voluntary muscle and causes a
decrease in muscle tone by interfering with the release of ionic calcium from
the sarcoplasmic reticulum in muscle cells due to inhibition of ryanodine
receptor (RYR) channels. Quinine has a curare-like effect on the motor
endplate and directly reduces tone by altering the intracellular distribution
of calcium. It is used to reduce the frequency of nocturnal leg cramps. Other
centrally acting compounds include carisoprodol, chlorphensin, chlorzoxazone,
diazepam, meprobamate and orphenadrine.
Musculotropic
spasmolytics act by a variety of mechanisms which include inhibition of
phosphodiesterases, inhibition of sodium-dependent cAMP-mediated Ca2+ efflux,
calcium channel antagonism and inhibition of adenosine reuptake carriers their
effects probably due to a mixture of these mechanisms. Examples include
papaverine (used for erectile dysfunction), ethaverine (a vasodilator used to
treat circulatory disorders), moxaverine, caroverine and tiropramide.
Neurotropic-
musculotropic
spasmolytics have both musculotropic spasmolytic actions and parasympatholytic
effects. Examples include dicyclomine (used to treat smooth muscle spasms in
the intestines), oxybutinin (used to treat urinary frequency, urinary
incontinence and neurogenic bladder instability) and flavoxate (used for
urinary frequency, urinary incontinence and bladder spasms due to
catheterization.
5)
Other muscle relaxants include calcium antagonists which act
in vascular smooth muscle causing vasodilation. Examples include nifedipine,
nitrendipine, verapamil and diltiazem.
Musculotropics: drugs affecting, attracted to or acting directly upon muscle
tissue which are used as muscle relaxants. Examples of musculotropics
include the papaverine-like spasmolytic agents such as papaverine, ethaverine
and moxaverine.
Musk
shrew: also known as the house musk shrew (Suncus murinus), has
become an animal model for motion sickness and for investigations into the
effects of emetics and antiemetics (rats cannot be used as they cannot vomit).
The musk shrew is widely distributed in tropical and subtropical regions of the
world and is commercially available from animal suppliers. This animal appears
to respond to both emetic and anti-emetic drugs like humans and retches and
vomits in response to certain kinds of intense motion.
Mustard
gas: also known as ypertite, an oily liquid used in chemical warfare.
It is a severe vesicant (it causes skin blistering), potent eye irritant and
can cause respiratory failure.
Mutagenesis: relating to the generation of mutations in genes. Mutagens are
substances causing mutations.
Mutual
prodrug: a type of carrier-linked prodrug.
Mycophenolic
acid (MPA): also known as mycophenolate, an
immunosuppressant and antibiotic substance derived from Penicillium
stoloniferum. It inhibits de novo synthesis of guanosine nucleotides
by selective, uncompetitive and reversible inhibition of inosine monophosphate
dehydrogenase . MPA inhibits the proliferation of T-cells, lymphocytes and the
formation of antibodies from B-cells and may also inhibit recruitment of
leukocytes into inflammatory sites.
It is used for the prophylaxis of organ rejection in patients
receiving allogeneic renal transplants and is usually administered in
combination with cyclosporine and corticosteroids. It has also been used to
treat severe refractory eczema.
Mycotoxins:
toxins produced by fungi. Examples include ergot, botulinum and
ochratoxins.
Mydriatic: a drug which causes mydriasis, dilation of the pupil of the eye.
Mydriatic
alkaloids: also known as belladona alkaloids, alkaloids obtained from Atropa
belladonna and other solanaceous plants. These alkaloids dilate the pupil
of the eye and examples include hyoscyamine and atropine.
Myenteric
plexus-longitudinal muscle preparation (MPLM): a
muscle preparation commonly obtained from the guinea pig ileum which has one of
the highest acetylcholine contents and richest cholinergic innervation
of known mammalian tissues. Originally introduced by Paton and Zar in
1968, this tissue comprises ganglionic and neuromuscular synapses and has been
used to investigate the role of both nicotinic and muscarinic agonists on
mammalian muscle tissue.
Paton
WD, Zar MA. The origin of acetylcholine released from guinea-pig intestine and
longitudinal muscle strips. J Physiol (1968) 194(1):13-33
Myoneural
agents: compounds which facilitate or inhibit the contraction of striated
muscle at the neuromuscular junction, ie compunds which affect cholinergic
transmission. Myoneural compounds act in at least three ways; by receptor
blockade such as that caused by curare, by affecting the activity of cholinesterase
such as the potentiation caused by neostigmine and by affecting the
syntheis and/or release of ACh such as that observed with botulinum
toxin.
|